Grimm, Oliver http://orcid.org/0000-0002-0767-0301
Thomä, Lara
Kranz, Thorsten M.
Reif, Andreas http://orcid.org/0000-0002-0992-634X
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (667302, 667302, 667302, 667302)
Deutsche Forschungsgemeinschaft (445498183)
Article History
Received: 22 November 2021
Revised: 23 May 2022
Accepted: 26 May 2022
First Online: 29 June 2022
Competing interests
: Prof. Dr. Andreas Reif received personal fees from MEDICE Arzneimittel Pütter GmbH & Co. KG, Shire PLC, neuraxpharm Arzneimittel GmbH, Janssen-Cilag GmbH and Servier Deutschland GmbH present or during 36 months prior to publication. Oliver Grimm received personal fees from MEDICE Arzneimittel Pütter GmbH & Co. KG. The remaining authors declare no competing interests.